Clinical Report: Testosterone Levels and Cardiovascular Health in Men
Overview
Lower endogenous testosterone levels in aging men are associated with higher all-cause and cardiovascular mortality, particularly below specific thresholds. Recent randomized controlled trials indicate testosterone treatment does not increase major cardiovascular events and may reduce type 2 diabetes risk in men with dysglycemia.
Background
Testosterone plays a crucial role in male sexual development, body composition, and bone mass maintenance. Circulating testosterone levels decline with age and are inversely related to obesity and comorbidities such as diabetes. The relationship between testosterone and cardiovascular disease (CVD) is complex, with lower levels often observed in men with preexisting CVD, though causality remains uncertain. Large epidemiological studies and recent clinical trials have sought to clarify these associations and the safety of testosterone supplementation.
Data Highlights
Study
Population
Testosterone Measurement
Key Findings
UK Biobank
208,677 men aged 40-69
Immunoassay
Lower testosterone associated with higher all-cause mortality but not incident CVD events
Testosterone treatment reduced risk of type 2 diabetes over 2 years
TRAVERSE Trial
Men with CVD or multiple risk factors
Randomized controlled trial
No increased risk of major adverse cardiovascular events over 3 years
Key Findings
Lower endogenous testosterone concentrations are more strongly associated with higher BMI and age than with cardiovascular disease alone.
UK Biobank data show lower testosterone correlates with increased all-cause mortality but not with incident cardiovascular events.
The AIMS meta-analysis identified threshold testosterone levels below which cardiovascular and all-cause mortality risks increase.
The T4DM trial demonstrated that testosterone therapy reduces progression to type 2 diabetes in men with dysglycemia.
The TRAVERSE trial found no increased cardiovascular risk with testosterone treatment in men with existing CVD or multiple risk factors over a 3-year period.
Clinical Implications
Clinicians should consider that low testosterone levels may serve as a biomarker for poor health rather than a direct cause of cardiovascular disease. Testosterone therapy appears safe in men with cardiovascular risk factors when monitored appropriately, and may offer metabolic benefits such as reducing diabetes risk. Long-term cardiovascular safety and benefits require further investigation to guide treatment decisions.
Conclusion
Current evidence suggests that while low testosterone levels are associated with increased mortality, testosterone supplementation does not increase cardiovascular risk in men with risk factors and may improve metabolic outcomes. Further studies are needed to confirm long-term safety and potential cardiovascular benefits.
References
Author/Source/2024 -- The Impact of Natural Testosterone Levels and Supplementation on Cardiovascular Health in Men
